FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
60.006,06 +494,00 (+0,83%)
Aeterna Zentaris Inc. (AEZS.TO)
| Chiusura precedente | 2,6700 |
| Aperto | 2,6700 |
| Denaro | 2,6700 x 0 |
| Lettera | 2,7300 x 0 |
| Min-Max giorno | 2,6700 - 2,6700 |
| Intervallo di 52 settimane | 1,9100 - 4,4800 |
| Volume | |
| Media Volume | 1.891 |
| Capitalizzazione | 12,965M |
| Beta (5 anni mensile) | 2,07 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,7100 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 11 ago 1999 |
| Stima target 1A | N/D |
GlobeNewswireAeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate a
- GlobeNewswire
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually. Dr. P
- GlobeNewswire
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o
